14 May 2026Open access
KIT-dependent acute myeloid leukemias are responsive to LSD1 inhibitionPublisher siteClinical Epigenetics, Epigenetics and DNA Methylation
Active, last published 2026
In acute myeloid leukemia research
Amal Kamal
Abdel‐Aziz
Scholar“Research focused on Acute Myeloid Leukemia Research and adjacent fields.”
Ain Shams University
Egypt
Claim Your ProfileEgypt21
H-index
3.9k
Citations
Amal has not officially claimed their profile. If you are Amal, claim it free.
Claim Your Profile
Pioneer
LOCKED
Pathfinder
LOCKED
Scholar
EARNED
Innovator
LOCKED
Inventor
LOCKED
Catalyst
LOCKED
Expert
UPGRADE
01 · About the work
What I study
mal Kamal Abdel‐Aziz is a researcher working on Acute Myeloid Leukemia Research. A fuller summary will appear once they update their profile.
02 · Reach
Publication output and reach
Amal's work has been cited 3,929 times across 3 active years. Bars show publications per year; the line shows cumulative citation totals across publications first appearing in each year.
03 · Research focus
Topics
Acute Myeloid Leukemia Research×9Autophagy in Disease and Therapy×7PI3K/AKT/mTOR signaling in cancer×4Chronic Myeloid Leukemia Treatments×4Histone Deacetylase Inhibitors Research×4
04 · Where I am
Affiliations
Affiliation on published researchAin Shams University, EgyptDrawn from the institution listed on this researcher’s published work.
Research themes (UN SDGs)
05 · Selected work
Recent publications
10 works14 May 2026Open access
Additional file 1 of KIT-dependent acute myeloid leukemias are responsive to LSD1 inhibitionPublisher siteFigshare, Mast cells and histamine
14 May 2026Open access
KIT-dependent acute myeloid leukemias are responsive to LSD1 inhibitionPublisher siteFigshare
14 May 2026Open access
KIT-dependent acute myeloid leukemias are responsive to LSD1 inhibitionPublisher siteFigshare
14 May 2026Open access
Additional file 1 of KIT-dependent acute myeloid leukemias are responsive to LSD1 inhibitionPublisher siteFigshare, Mast cells and histamine
1 May 2025Open access3cites
Structural Optimization and MD Simulation Study of Benzimidazole Derivatives as Potent Mutant FLT3 Kinase Inhibitors Targeting AMLPublisher siteArchiv der Pharmazie, Chronic Myeloid Leukemia Treatments
12 Nov 2024Open access3cites
OXPHOS mediators in acute myeloid leukemia patients: Prognostic biomarkers and therapeutic targets for personalized medicinePublisher siteWorld Journal of Surgical Oncology, Acute Myeloid Leukemia Research
5 Nov 20241cites
Anticancer activity of EMD37 against human head and neck cancer: Impact on apoptotic and inflammatory machineriesPublisher siteToxicology in Vitro, Peptidase Inhibition and Analysis
Expert Academic Profiles go further
Citation trend analytics, exportable publication records, and direct enquiry routing from industry and funders.
Are you Amal?
Claim it to verify your details, connect with industry partners, and explore Fractional Domain Expert opportunities through MARATTO™.
African researchers are full of potential that too often goes unrecognised. Your MARATTO™ profile gives your work the commercial pathway it deserves.
Claim Your Profile
Free to claim · takes a minute to verify it’s you